Survival outcomes in phase I trial combining VCN-01 and durvalumab (MEDI4736) in subjects with recurrent/ metastatic head and neck squamous cell carcinoma refractory to previous immunotherapy treatment

被引：0

作者：

Jove, M. ^{[1
]}

Brana, I. ^{[2
,3
]}

Oliva Bernal, M. ^{[4
]}

Hernando Calvo, A.

Erasun Lecuona, C. ^{[4
]}

Assaf Pastrana, J. D. ^{[2
,3
]}

Mato-Berciano, A. ^{[5
]}

V. Maliandi, M. ^{[5
]}

Torres-Manjon, S. ^{[6
]}

Moreno, R. ^{[6
]}

Le, C. ^{[7
]}

G. Nuciforo, P. ^{[8
]}

Alemany, R. ^{[6
]}

Capella, G. ^{[9
]}

Blasco, C. ^{[10
]}

Cascallo Piqueras, M. ^{[10
]}

Mesia Nin, R. ^{[11
]}

机构：

[1] Catalan Inst Oncol ICO, Med Oncol Phase Funct Unit 1, Lhospitalet De Llobregat, Spain

[2] Vall dHebron Hosp Univ, Med Oncol Dept, Barcelona, Spain

[3] Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[4] Catalan Inst Oncol ICO, Med Oncol Phase Funct Unit 1, Barcelona, Spain

[5] Theriva Biol, R&D, Parets Del Valles, Spain

[6] ICO Inst Catala Oncol Hosp Duran I Reynals, IDIBELL, ProCure Program ICO Program Mol Mech & Expt Ther, Lhospitalet De Llobregat, Spain

[7] Theriva Biol, Stat & Analyt, Rockville, MD USA

[8] Vall dHebron Inst Oncol VHIO Cellex Ctr, Mol Oncol Dept, Barcelona, Spain

[9] IDIBELL, Program Mol Mech & Expt Therapy Oncol Oncobell, Lhospitalet De Llobregat, Spain

[10] Theriva Biol, Clin Operat, Parets Del Valles, Spain

[11] IGTP, ICO Inst Catala Oncol, Med Oncol Dept, B ARGO Grp, Badalona, Spain

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2081

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

937P

引用

页码：S589 / S590

页数：2

共 50 条

[31] Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial
Guigay, Joel
Lee, Keun-Wook
Patel, Manish R.
Daste, Amaury
Wong, Deborah J.
Goel, Sanjay
Gordon, Michael S.
Gutierrez, Martin
Balmanoukian, Ani
Le Tourneau, Christophe
Mita, Alain
Vansteene, Damien
Keilholz, Ulrich
Schoffski, Patrick
Grote, Hans Juergen
Zhou, Dongli
Bajars, Marcis
Penel, Nicolas
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (10)
[32] Setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head & neck: Results of a randomized, double-blind phase II trial
Fayette, J.
Thomas, G.
Daste, A.
Rotarski, M.
Castelo, B.
Rullan, A.
Levine, A.
Philipson, R. S.
Harrington, K. J.
ANNALS OF ONCOLOGY, 2024, 35 : S615 - S616
[33] A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
Galot, R.
Le Tourneau, C.
Licitra, L. F. L.
Even, C.
Daste, A.
Henry, S.
Borel, C.
Abdeddaim, C.
Seront, E.
Prevost, J. B.
Rutten, A.
Saada, E. B.
Rolland, F.
Livi, L.
Specenier, P. M. C.
Leys, J.
Olungu, C.
Lefevre, C. Fortpied
Joaquim, A.
Machiels, J-P.
ANNALS OF ONCOLOGY, 2023, 34 : S588 - S589
[34] Cabazitaxel in patients with refractory recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Results of phase II trial unicancer ORL03.
Fayette, Jerome
Guigay, Joel
Le Toumeau, Christophe
Degardin, Marian
Peyrade, Frederic
Orlandini, Florence
Buffard, Karine
Bellera, Carine A.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[35] Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Marret, Gregoire
Isambert, Nicolas
Rezai, Keyvan
Gal, Jocelyn
Saada-Bouzid, Esma
Rolland, Frederic
Chausson, Maggy
Borcoman, Edith
Alt, Marie
Klijanienko, Jerzy
Vansteene, Damien
Guigay, Joel
Kamal, Maud
Bieche, Ivan
Le Tourneau, Christophe
INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1641 - 1648
[36] Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Grégoire Marret
Nicolas Isambert
Keyvan Rezai
Jocelyn Gal
Esma Saada-Bouzid
Frédéric Rolland
Maggy Chausson
Edith Borcoman
Marie Alt
Jerzy Klijanienko
Damien Vansteene
Joël Guigay
Maud Kamal
Ivan Bièche
Christophe Le Tourneau
Investigational New Drugs, 2021, 39 : 1641 - 1648
[37] Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Babiker, Hani
Brana, Irene
Mahadevan, Daruka
Owonikoko, Taofeek
Calvo, Emiliano
Rischin, Danny
Moreno, Victor
Papadopoulos, Kyriakos P.
Crittenden, Marka
Formenti, Silvia
Giralt, Jordi
Garrido, Pilar
Soria, Ainara
Hervas-Moron, Asuncion
Mohan, Kosalai Kal
Fury, Matthew
Lowy, Israel
Mathias, Melissa
Feng, Minjie
Li, Jingjin
Stankevich, Elizabeth
ONCOLOGIST, 2021, 26 (09): : E1508 - E1513
[38] RAMUCIRUMAB IN COMBINATION WITH PEMBROLIZUMAB AS FIRST-LINE TREATMENT FOR RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS-CELL CARCINOMA: A PHASE 1-2 TRIAL
Adkins, Douglas
Ley, Jessica
Palka, Kevin
Jacobs, Miriam
Liu, Jingxia
Oppelt, Peter
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A385 - A385
[39] Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck
Taguchi, Jun
Shimizu, Yasushi
Ariga, Shin
Goda, Tomohiro
Ohhara, Yoshihito
Honma, Rio
Noguchi, Takuro
Takeuchi, Satoshi
Kinoshita, Ichiro
Amano, Toraji
Mizumachi, Takatsugu
Kano, Satoshi
Takahara, Miki
Abe, Takahisa
Homma, Akihiro
Dosaka-Akita, Hirotoshi
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (01) : 51 - 58
[40] A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma
Swiecicki, P. L.
Durm, G.
Bellile, E.
Brummel, C.
Pang, M.
Bhangale, A.
Brenner, J. C.
Worden, F.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (05): : 1178 - 1179

← 1 2 3 4 5 →